stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Book value per share
GeneDx Holdings Corp.'s book value per share at the end of fiscal 2025 was 10.8×, up 18.0% from 9.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 8.2×. Over the past ten years it has ranged from 0.0× (fiscal 2019) to 28,222× (fiscal 2020); the current reading is higher than 57% of that period. GeneDx Holdings Corp. ranks 24th of 49 Diagnostics & Research companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 10.8× | 17.98% |
| FY2024 | 9.1× | (2.76%) |
| FY2023 | 9.4× | (62.16%) |
| FY2022 | 24.8× | (79.09%) |
| FY2021 | 119× | (99.58%) |
| FY2020 | 28,222× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 8.2× | (5.11%) |
| Mar 2026 | 8.7× | (19.49%) |
| Dec 2025 | 10.8× | 6.02% |
| Sep 2025 | 10.1× | 4.66% |
| 21 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| VCYT Veracyte, Inc. compare | 17.8× |
| CSTL Castle Biosciences, Inc. compare | 15.6× |
| CDNA CareDx, Inc. compare | 9.0× |
| WGS GeneDx Holdings Corp. | 8.2× |
| NEO NeoGenomics, Inc. compare | 6.2× |
| PSNL Personalis, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. compare | 1.5× |
| ADPT Adaptive Biotechnologies Corporation compare | 1.1× |
| FRNM Freenome, Inc compare | −2.6× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement